Multi-Stage, Mutation Resistant HIV Drug Efficiency study employing Bag’s Relative IC50 Method of Mx(CO)y(µ - H)(µ - (CH2)2COO−)Na+
Abstract
The search for a highly active, multi-stage, mutation registrant HIV-1 drug is very urgent due to its high mutation rate that causes the ongoing HIV epidemic. Since the current HIV treatments fail against drug-resistant strains, the quest for a mutation-resistant drug is in high demand. To replace the present practice of highly active antiretroviral therapy (HAART), which involves the use of three or more drugs from different classes of antiretroviral drugs to target different stages of the virus’s life cycle that may cause adverse side effects, herein a new drug is proposed which is effective to act as an inhibitor to the most of the enzymes of an HIV life cycle. It is observed that the presently prescribed drug candidate, Ru5(CO)14(µ - H)(µ -S(CH2)2 COO−)Na+, is not only capable to inhibit most enzymes of an HIV life cycle, but its inhibition capacities (IC50 values in pico mole are 96.6 as nucleoside reverse transcriptase inhibitors (NRTIs), 0.89 as non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.61 as nucleotide reverse transcriptase inhibitors (NtRTI), 9.74 as protease inhibitors (PIs), 3.16 as CCR5 inhibitors, and 494 as Integrase inhibitors (INI) are also higher than the corresponding Food and Drug Administration approved commonly used drugs of that category. Thus, Ru5(CO)14(µ - H)(µ -S(CH2)2 COO−)Na+ will be effective multi-stage mutation resistrant HIV drug.
Abstract
The search for a highly active, multi-stage, mutation registrant HIV-1 drug is very urgent due to its high mutation rate that causes the ongoing HIV epidemic. Since the current HIV treatments fail against drug-resistant strains, the quest for a mutation-resistant drug is in high demand. To replace the present practice of highly active antiretroviral therapy (HAART), which involves the use of three or more drugs from different classes of antiretroviral drugs to target different stages of the virus’s life cycle that may cause adverse side effects, herein a new drug is proposed which is effective to act as an inhibitor to the most of the enzymes of an HIV life cycle. It is observed that the presently prescribed drug candidate, Ru5(CO)14(µ - H)(µ -S(CH2)2 COO−)Na+, is not only capable to inhibit most enzymes of an HIV life cycle, but its inhibition capacities (IC50 values in pico mole are 96.6 as nucleoside reverse transcriptase inhibitors (NRTIs), 0.89 as non-nucleoside reverse transcriptase inhibitors (NNRTIs), 0.61 as nucleotide reverse transcriptase inhibitors (NtRTI), 9.74 as protease inhibitors (PIs), 3.16 as CCR5 inhibitors, and 494 as Integrase inhibitors (INI) are also higher than the corresponding Food and Drug Administration approved commonly used drugs of that category. Thus, Ru5(CO)14(µ - H)(µ -S(CH2)2 COO−)Na+ will be effective multi-stage mutation resistrant HIV drug.